MED.00151 Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency

This policy addresses gene therapy for aromatic L‑amino acid decarboxylase (AADC) deficiency using eladocagene exuparvovec‑tneq. Anthem considers this therapy investigational/experimental and not medically necessary; therefore, it is not covered for any indication. There are no covered circumstances or exceptions under this policy, and related services (e.g., billed under 64999, C9399, J3490, J3590) are subject to denial.

"Gene therapy for aromatic l-amino acid decarboxylase deficiency using eladocagene exuparvovec-tneq is consideredinvestigational and not medically necessaryfor all indications."

Sign up to see full coverage criteria, indications, and limitations.